



Ethics application approved for preclinical study at Skåne University Hospital



NanoEcho will conduct a preclinical study led by Henrik Thorlacius, Professor of Surgery at Lund University and Chief Physician at Skåne University Hospital in Malmö, in which NanoEcho's new instrument for detection of lymph nodes with cancer spread will be evaluated. The study will be carried out at Skåne University Hospital in Malmö and will include about 40 patients that will undergo the usual routine standard surgery. Once the cancer is removed from the patient, the surgical prepartate will be examined with NanoEcho's instrument. The result will then be compared with the pathologist's fin

- My hope for the clinical trial is that we will be able to validate that NanoEcho's instrument is able to provide high-precision identification of lymph nodes containing cancer cells. If so, we will proceed with further clinical trials, where NanoEcho's instrument will be evaluated in patients prior to surgery, says Henrik Thorlacius.
- I am very pleased to announce that our joint ethics application has been approved. This entails that we will implement our preclinical trials at two of the major university hospitals in Sweden, in Gothenburg and Skåne. We are currently discussing a start date for the study, and we hope to be able to commence with this study as well during the second quarter. The start date may of course be affected by the prevailing COVID-19 restrictions. I look forward to get started with the study and look with expectation to the outcome, says Linda Persson, NanoEcho's CEO.

[Link to a short video where Henrik Thorlacius tells more about the study.](#)



If you have any questions, please contact

Annika Andersson
CCO
E-mail: aan@nanoecho.se

NanoEcho has developed a new technology for clearer diagnostics of, as the first phase, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simpler and less costly diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalized treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs.

www.nanoecho.se